Lipoic acid pellet composition
The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients.
1. A composition comprising pellets of lipoic acid, or one of its salts, carried in a lipophilic medium, wherein said pellets are particles consisting of an inert nucleus coated in (i) lipoic acid; (ii) a first layer of insulating polymeric material applied on said lipoic acid coating, wherein said first layer is hydroxypropylmethylcellulose or hydroxypropylcellulose; and (iii) a second polymeric layer resistant to gastric pH applied on said first layer, wherein said second layer comprises one or more compounds selected from the group consisting of esters of cellulose, polyvinylacetate phthalate, copolymers of methacrylic acid and esters of methylacrylate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, copolymers of esters of acrylic and methacrylic acid, and shellac, wherein said lipophilic medium is a pharmaceutically acceptable component.
2. Composition as claimed in claim 1 , wherein said lipophilic medium has anti-oxidant properties.
3. Composition as claimed in claim 1 , wherein said lipophilic medium comprises (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-docosaesaenoic acid (DHA).
4. Composition as claimed in claim 1 , wherein said lipophilic medium is fish oil or cod liver oil.
5. Composition as claimed in claim 4 , wherein said lipophilic medium is fish oil or cod liver oil in a purified form and enriched in Omega 3 polyunsaturated fatty acids.
6. Composition as claimed in claim 5 , wherein said lipophilic medium is enriched in EPA and DHA.
7. Composition as claimed in claim 1 , wherein said lipophilic medium comprises gamma-linolenic acid.
8. Composition as claimed in claim 1 , further comprising an active ingredient selected from the group consisting of gabapentin, pregabalin, olmesartan captopril, interferon, acamprosate and megestrol.
9. Composition as claimed in claim 1 , further comprising benfotiamine.
10. The composition as claimed in claim 1 , wherein a dosage unit comprises between 100 and 1000 mg of fish oil or cod liver oil in purified form.
11. The composition as claimed in claim 1 , wherein a dosage unit comprises between 100 and 3000 mg of a mixture of EPA and DHA.
12. The composition as claimed in claim 1 , wherein a dosage unit comprises 300-1000 mg of gamma-linolenic acid.
13. The omposition as claimed in claim 1 , wherein a dosage unit further comprises an active ingredient selected from the group consisting of gabapentin, pregabalin, olmesartan captopril, interferon, acamprosate and megestrol.
14. Composition as claimed in claim 1 , further comprising an active ingredient with antioxidant action.
15. A method for treatment of oxidative stress which comprises administering, to a subject in need thereof, a composition comprising pellets of lipoic acid, or one of its salts, carried in a lipophilic medium, wherein said pellets are particles consisting of an inert nucleus coated in (i) lipoic acid; (ii) a first layer of insulating polymeric material applied on said lipoic acid coating, wherein said first layer is hydroxypropylmethylcellulose or hydroxypropylcellulose; and (iii) a second polymeric layer resistant to gastric pH applied on said first layer, wherein said second layer comprises one or more compounds selected from the group consisting of esters of cellulose, polyvinylacetate phthalate, copolymers of methacrylic acid and esters of methylacrylate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, copolymers of esters of acrylic and methacrylic acid, and shellac wherein said lipophilic medium is a pharmaceutically acceptable component.